{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:43:16Z","timestamp":1793245396195,"version":"4.5.0"},"reference-count":296,"publisher":"Harborside Press, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paragangliomas, and multiple endocrine neoplasia. NETs are generally subclassified by site of origin, stage, and histologic characteristics. Appropriate diagnosis and treatment of NETs often involves collaboration between specialists in multiple disciplines, using specific biochemical, radiologic, and surgical methods. Specialists include pathologists, endocrinologists, radiologists (including nuclear medicine specialists), and medical, radiation, and surgical oncologists. These guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine and adrenal tumors and are intended to assist with clinical decision-making. This article is focused on the 2021 NCCN Guidelines principles of genetic risk assessment and counseling and recommendations for well-differentiated grade 3 NETs, poorly differentiated neuroendocrine carcinomas, adrenal tumors, pheochromocytomas, and paragangliomas.<\/jats:p>","DOI":"10.6004\/jnccn.2021.0032","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T14:20:35Z","timestamp":1627914035000},"page":"839-868","source":"Crossref","is-referenced-by-count":553,"title":["Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"19","author":[{"given":"Manisha H.","family":"Shah","sequence":"first","affiliation":[{"name":"1The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney S.","family":"Goldner","sequence":"additional","affiliation":[{"name":"2Fred & Pamela Buffett Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al B.","family":"Benson","sequence":"additional","affiliation":[{"name":"3Robert H. Lurie Comprehensive Cancer Center of Northwestern University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bergsland","sequence":"additional","affiliation":[{"name":"4UCSF Helen Diller Family Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Blaszkowsky","sequence":"additional","affiliation":[{"name":"5Massachusetts General Hospital Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Brock","sequence":"additional","affiliation":[{"name":"1The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chan","sequence":"additional","affiliation":[{"name":"6Dana-Farber\/Brigham and Women\u2019s Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satya","family":"Das","sequence":"additional","affiliation":[{"name":"7Vanderbilt-Ingram Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paxton V.","family":"Dickson","sequence":"additional","affiliation":[{"name":"8St. Jude Children's Research Hospital\/The University of Tennessee Health Science Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Fanta","sequence":"additional","affiliation":[{"name":"9UC San Diego Moores Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Giordano","sequence":"additional","affiliation":[{"name":"10University of Michigan Rogel Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[{"name":"11Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Halperin","sequence":"additional","affiliation":[{"name":"12The University of Texas MD Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[{"name":"13The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Heaney","sequence":"additional","affiliation":[{"name":"14UCLA Jonsson Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Heslin","sequence":"additional","affiliation":[{"name":"15O'Neal Comprehensive Cancer Center at UAB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Kandeel","sequence":"additional","affiliation":[{"name":"16City of Hope National Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Kardan","sequence":"additional","affiliation":[{"name":"17Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajid A.","family":"Khan","sequence":"additional","affiliation":[{"name":"18Yale Cancer Center\/Smilow Cancer Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris W.","family":"Kuvshinoff","sequence":"additional","affiliation":[{"name":"19Roswell Park Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lieu","sequence":"additional","affiliation":[{"name":"20University of Colorado Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Miller","sequence":"additional","affiliation":[{"name":"2Fred & Pamela Buffett Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venu G.","family":"Pillarisetty","sequence":"additional","affiliation":[{"name":"21Fred Hutchinson Cancer Research Center\/Seattle Cancer Care Alliance;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Reidy","sequence":"additional","affiliation":[{"name":"22Memorial Sloan Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarimar Agosto","family":"Salgado","sequence":"additional","affiliation":[{"name":"23UT Southwestern Simmons Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagufta","family":"Shaheen","sequence":"additional","affiliation":[{"name":"24Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heloisa P.","family":"Soares","sequence":"additional","affiliation":[{"name":"25Huntsman Cancer Institute at the University of Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Soulen","sequence":"additional","affiliation":[{"name":"26Abramson Cancer Center at the University of Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Strosberg","sequence":"additional","affiliation":[{"name":"27Moffitt Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig R.","family":"Sussman","sequence":"additional","affiliation":[{"name":"7Vanderbilt-Ingram Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos A.","family":"Trikalinos","sequence":"additional","affiliation":[{"name":"28Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya A.","family":"Uboha","sequence":"additional","affiliation":[{"name":"29University of Wisconsin Carbone Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Vijayvergia","sequence":"additional","affiliation":[{"name":"30Fox Chase Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Wong","sequence":"additional","affiliation":[{"name":"31Duke Cancer Institute; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Lynn","sequence":"additional","affiliation":[{"name":"32National Comprehensive Cancer Network;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Hochstetler","sequence":"additional","affiliation":[{"name":"32National Comprehensive Cancer Network;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref1831","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jamcollsurg.2013.11.001","article-title":"Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors","volume":"218","author":"Qadan","year":"2014","journal-title":"J Am Coll Surg"},{"key":"ref2661","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMc1101502","article-title":"Drugs and pheochromocytoma--don\u2019t be fooled by every elevated metanephrine","volume":"364","author":"Neary","year":"2011","journal-title":"N Engl J Med"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1023\/A:1008377915129","article-title":"Streptozocin and o,p\u2019DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use","volume":"11","author":"Khan","year":"2000","journal-title":"Ann Oncol"},{"key":"ref2761","volume-title":"Textbook of Endocrine Surgery","author":"Clark","year":"1997"},{"key":"ref2011","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc2031965","article-title":"The spectrum of benefit from checkpoint blockade in hypermutated tumors","volume":"384","author":"Rousseau","year":"2021","journal-title":"N Engl J Med"},{"key":"ref2211","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4149\/endo_2011_02_65","article-title":"Phaeochromocytoma: a catecholamine and oxidative stress disorder","volume":"45","author":"Pacak","year":"2011","journal-title":"Endocr Regul"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1200\/JCO.2012.47.3884","article-title":"Are neuroendocrine tumors going mainstream?","volume":"31","author":"Kulke","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref2811","first-page":"39","article-title":"Azedra\u00ae (iobenguane I 131) in patients with metastatic and\/or recurrent and\/or unresectable pheochromocytoma or paraganglioma: biochemical tumor marker results of a multicenter, open-label pivotal phase 2b study. Abstract OR02-5","author":"Jimenez","year":"2018","journal-title":"Endocr Rev"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-129-6-199809150-00011","article-title":"Multiple endocrine neoplasia type 1: clinical and genetic topics","volume":"129","author":"Marx","year":"1998","journal-title":"Ann Intern Med"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1245\/s10434-008-0192-8","article-title":"A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients","volume":"16","author":"Landry","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1200\/JCO.2008.17.2775","article-title":"Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma","volume":"27","author":"Veytsman","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref1771","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1245\/s10434-008-0192-8","article-title":"A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients","volume":"16","author":"Landry","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12029-015-9689-0","article-title":"Treatment of high-grade metastatic pancreatic neuroendocrine carcinoma with FOLFIRINOX","volume":"46","author":"Zhu","year":"2015","journal-title":"J Gastrointest Cancer"},{"key":"ref1931","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-15-0548","article-title":"Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas","volume":"22","author":"Tang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/bjs.10414","article-title":"European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma","volume":"104","author":"Gaujoux","year":"2017","journal-title":"Br J Surg"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref2111","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5603\/EP.a2019.0010","article-title":"Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis","volume":"70","author":"Rogowski","year":"2019","journal-title":"Endokrynol Pol"},{"key":"ref2481","doi-asserted-by":"crossref","first-page":"9362108","DOI":"10.1155\/2018\/9362108","article-title":"Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis","volume":"2018","author":"Tang","year":"2018","journal-title":"BioMed Res Int"},{"key":"ref2381","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.acra.2017.12.005","article-title":"Combining washout and noncontrast data from adrenal protocol CT: improving diagnostic performance","volume":"25","author":"Ng","year":"2018","journal-title":"Acad Radiol"},{"key":"ref2741","volume-title":"GeneReviews","author":"Else","year":"2008"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5603\/EP.a2019.0010","article-title":"Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis","volume":"70","author":"Rogowski","year":"2019","journal-title":"Endokrynol Pol"},{"key":"ref2701","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N Engl J Med"},{"key":"ref2651","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2791","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cncr.11518","article-title":"High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma","volume":"98","author":"Rose","year":"2003","journal-title":"Cancer"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41379-018-0076-9","article-title":"The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence","volume":"31","author":"Marchevsky","year":"2018","journal-title":"Mod Pathol"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1210\/jc.2013-3020","article-title":"Update in adrenocortical carcinoma","volume":"98","author":"Fassnacht","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/ERC-15-0075","article-title":"Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma","volume":"22","author":"Hadoux","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"ref1801","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1200\/JCO.2012.47.3884","article-title":"Are neuroendocrine tumors going mainstream?","volume":"31","author":"Kulke","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1477-2574.2009.00082.x","article-title":"A simplified prognostic system for resected pancreatic neuroendocrine neoplasms","volume":"11","author":"Ballian","year":"2009","journal-title":"HPB (Oxford)"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jamcollsurg.2007.05.009","article-title":"Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors","volume":"205","author":"Bilimoria","year":"2007","journal-title":"J Am Coll Surg"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","article-title":"The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer","volume":"39","author":"Chen","year":"2010","journal-title":"Pancreas"},{"key":"ref2491","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1159\/000227608","article-title":"Adrenocortical carcinoma: experience in 45 patients","volume":"54","author":"Barzon","year":"1997","journal-title":"Oncology"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1159\/000227608","article-title":"Adrenocortical carcinoma: experience in 45 patients","volume":"54","author":"Barzon","year":"1997","journal-title":"Oncology"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2012.44.5924","article-title":"Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors","volume":"31","author":"Strosberg","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref1941","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PAS.0b013e3182417d36","article-title":"Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors","volume":"36","author":"Yachida","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"ref2281","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/j.seminoncol.2016.08.007","article-title":"Genetic predisposition to endocrine tumors: diagnosis, surveillance and challenges in care","volume":"43","author":"Petr","year":"2016","journal-title":"Semin Oncol"},{"key":"ref1811","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.2013.51.1477","article-title":"Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors","volume":"31","author":"Kim","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref2801","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2018.36.15_suppl.4005","article-title":"Azedra (iobenguane I 131) in patients with malignant, recurrent and\/or unresectable pheochromocytoma or paraganglioma (PPGL): updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study","volume":"36","author":"Pryma","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1245\/s10434-012-2746-z","article-title":"Neuroendocrine tumors of the colon and rectum: prognostic relevance and comparative performance of current staging systems","volume":"20","author":"Chagpar","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.15.S1.1","article-title":"The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas","volume":"15","author":"Zeiger","year":"2009","journal-title":"Endocr Pract"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/jmedgenet-2012-101192","article-title":"Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis","volume":"49","author":"van Hulsteijn","year":"2012","journal-title":"J Med Genet"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1530\/ERC-12-0002","article-title":"FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3","volume":"19","author":"Hentic","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"ref2021","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1158\/1078-0432.CCR-20-0621","article-title":"Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers","volume":"26","author":"Klein","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref2131","doi-asserted-by":"publisher","DOI":"10.1111\/jne.12950","article-title":"Outcomes of upfront treatment with mFOLFIRINOX regimen in monocentric retrospective experience th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease Virtual Conference Available athttps onlinelibrary wiley com doi pdf","volume":"18","author":"BorghesaniM","year":"2021"},{"key":"ref2631","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/cen.13434","article-title":"Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"87","author":"Hamidi","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/PAS.0000000000000408","article-title":"The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms","volume":"39","author":"Basturk","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"ref1321","first-page":"39","article-title":"Azedra\u00ae (iobenguane I 131) in patients with metastatic and\/or recurrent and\/or unresectable pheochromocytoma or paraganglioma: biochemical tumor marker results of a multicenter, open-label pivotal phase 2b study. Abstract OR02-5","author":"Jimenez","year":"2018","journal-title":"Endocr Rev"},{"key":"ref2191","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1210\/jc.2013-3020","article-title":"Update in adrenocortical carcinoma","volume":"98","author":"Fassnacht","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref1621","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1200\/JCO.2002.10.030","article-title":"Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups","volume":"20","author":"Hochwald","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"ref1701","volume-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2010"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bjc.1994.183","article-title":"Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients","volume":"69","author":"Haak","year":"1994","journal-title":"Br J Cancer"},{"key":"ref1721","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1245\/s10434-012-2746-z","article-title":"Neuroendocrine tumors of the colon and rectum: prognostic relevance and comparative performance of current staging systems","volume":"20","author":"Chagpar","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"ref1651","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cncr.23549","article-title":"Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors","volume":"113","author":"Pape","year":"2008","journal-title":"Cancer"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cncr.11518","article-title":"High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma","volume":"98","author":"Rose","year":"2003","journal-title":"Cancer"},{"key":"ref2321","first-page":"2559","article-title":"Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors","volume":"82","author":"Gicquel","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2721","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jnci\/djv053","article-title":"Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene","volume":"107","author":"Casc\u00f3n","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1148\/radiol.2223010766","article-title":"Adrenal masses: characterization with combined unenhanced and delayed enhanced CT","volume":"222","author":"Caoili","year":"2002","journal-title":"Radiology"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1016\/S1590-8658(11)60591-4","article-title":"Gastroenteropancreatic (neuro)endocrine neoplasms: the histology report","volume":"43","author":"Rindi","year":"2011","journal-title":"Dig Liver Dis"},{"key":"ref2201","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"ref2951","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","article-title":"Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma","volume":"4","author":"Tanabe","year":"2013","journal-title":"Horm Cancer"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.2012.47.1912","article-title":"New syndrome of paraganglioma and somatostatinoma associated with polycythemia","volume":"31","author":"Pacak","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref2271","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2012.48.0988","article-title":"Adrenocortical carcinoma is a lynch syndrome-associated cancer","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1399-0004.2011.01805.x","article-title":"Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex","volume":"82","author":"Larson","year":"2011","journal-title":"Clin Genet"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3803\/EnM.2017.32.2.152","article-title":"Update on modern management of pheochromocytoma and paraganglioma","volume":"32","author":"Lenders","year":"2017","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref2601","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3803\/EnM.2017.32.2.152","article-title":"Update on modern management of pheochromocytoma and paraganglioma","volume":"32","author":"Lenders","year":"2017","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jcem-72-2-455","article-title":"Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma","volume":"72","author":"Krempf","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"ref641","doi-asserted-by":"publisher","DOI":"10.1111\/jne.12950","article-title":"Outcomes of upfront treatment with mFOLFIRINOX regimen in monocentric retrospective experience th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease Virtual Conference Available athttps onlinelibrary wiley com doi pdf","volume":"18","author":"BorghesaniM","year":"2021"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jso.24553","article-title":"Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas","volume":"115","author":"Nastos","year":"2017","journal-title":"J Surg Oncol"},{"key":"ref2241","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-129-6-199809150-00011","article-title":"Multiple endocrine neoplasia type 1: clinical and genetic topics","volume":"129","author":"Marx","year":"1998","journal-title":"Ann Intern Med"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Heetfeld","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","volume":"8","author":"Merino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/modpathol.2016.217","article-title":"Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20","volume":"30","author":"Konukiewitz","year":"2017","journal-title":"Mod Pathol"},{"key":"ref1761","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jamcollsurg.2008.08.013","article-title":"Proposed staging system for colon carcinoid tumors based on an analysis of 2,459 patients","volume":"207","author":"Landry","year":"2008","journal-title":"J Am Coll Surg"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing\u2019s syndrome: an Endocrine Society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1210\/jc.2002-021069","article-title":"The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors","volume":"87","author":"Koch","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref2531","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref2941","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref671","first-page":"cncr.33591","article-title":"A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: high-grade neuroendocrine neoplasm cohort","author":"Patel","year":"2021","journal-title":"Cancer"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1245\/s10434-019-08049-5","article-title":"Surgery with radical intent: is there an indication for G3 neuroendocrine neoplasms?","volume":"27","author":"Merola","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"ref1911","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Heetfeld","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"ref2411","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1210\/clinem\/dgaa606","article-title":"Evolution of the primary aldosteronism syndrome: updating the approach","volume":"105","author":"Vaidya","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1210\/jc.2012-2198","article-title":"Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma","volume":"98","author":"Raymond","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref1411","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med"},{"key":"ref2621","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1200\/JCO.2011.34.6353","article-title":"Metastatic pheochromocytoma\/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations","volume":"29","author":"King","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref2151","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"9362108","DOI":"10.1155\/2018\/9362108","article-title":"Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis","volume":"2018","author":"Tang","year":"2018","journal-title":"BioMed Res Int"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jamcollsurg.2013.11.001","article-title":"Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors","volume":"218","author":"Qadan","year":"2014","journal-title":"J Am Coll Surg"},{"key":"ref2091","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/ERC-15-0075","article-title":"Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma","volume":"22","author":"Hadoux","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"ref1751","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.amjsurg.2008.07.042","article-title":"A proposed staging system for small bowel carcinoid tumors based on an analysis of 6,380 patients","volume":"196","author":"Landry","year":"2008","journal-title":"Am J Surg"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1634\/theoncologist.2007-0243","article-title":"Molecular markers and the pathogenesis of adrenocortical cancer","volume":"13","author":"Soon","year":"2008","journal-title":"Oncologist"},{"key":"ref1871","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1477-2574.2009.00082.x","article-title":"A simplified prognostic system for resected pancreatic neuroendocrine neoplasms","volume":"11","author":"Ballian","year":"2009","journal-title":"HPB (Oxford)"},{"key":"ref1951","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/modpathol.2016.217","article-title":"Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20","volume":"30","author":"Konukiewitz","year":"2017","journal-title":"Mod Pathol"},{"key":"ref1601","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41379-018-0076-9","article-title":"The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence","volume":"31","author":"Marchevsky","year":"2018","journal-title":"Mod Pathol"},{"key":"ref1791","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2012.44.5924","article-title":"Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors","volume":"31","author":"Strosberg","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMc1101502","article-title":"Drugs and pheochromocytoma--don\u2019t be fooled by every elevated metanephrine","volume":"364","author":"Neary","year":"2011","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1399-0004.2011.01805.x","article-title":"Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex","volume":"82","author":"Larson","year":"2011","journal-title":"Clin Genet"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1634\/theoncologist.2015-0476","article-title":"Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement","volume":"21","author":"Coriat","year":"2016","journal-title":"Oncologist"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1001\/archsurg.143.7.664","article-title":"Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system","volume":"143","author":"Landry","year":"2008","journal-title":"Arch Surg"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/cam4.1336","article-title":"Assessment of the American Joint Commission on Cancer 8th edition staging system for patients with pancreatic neuroendocrine tumors: A Surveillance, Epidemiology, and End Results analysis","volume":"7","author":"Li","year":"2018","journal-title":"Cancer Med"},{"key":"ref2771","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.amjsurg.2014.11.012","article-title":"Effectiveness and safety of laparoscopic adrenalectomy of large pheochromocytoma: a prospective, nonrandomized, controlled study","volume":"210","author":"Wang","year":"2015","journal-title":"Am J Surg"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1200\/JCO.2002.10.030","article-title":"Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups","volume":"20","author":"Hochwald","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref2841","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref2921","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EJE-09-0627","article-title":"The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective","volume":"163","author":"Guignat","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"ref1901","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1530\/ERC-13-0027","article-title":"Are G3 ENETS neuroendocrine neoplasms heterogeneous?","volume":"20","author":"V\u00e9layoudom-C\u00e9phise","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"ref2971","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref1271","volume-title":"Textbook of Endocrine Surgery","author":"Clark","year":"1997"},{"key":"ref2251","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1634\/theoncologist.2007-0243","article-title":"Molecular markers and the pathogenesis of adrenocortical cancer","volume":"13","author":"Soon","year":"2008","journal-title":"Oncologist"},{"key":"ref1921","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/PAS.0000000000000662","article-title":"A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas","volume":"40","author":"Tang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"ref2071","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/cncr.32750","article-title":"Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: a randomized phase 2 study","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1016\/S1590-8658(11)60591-4","article-title":"Gastroenteropancreatic (neuro)endocrine neoplasms: the histology report","volume":"43","author":"Rindi","year":"2011","journal-title":"Dig Liver Dis"},{"key":"ref1371","first-page":"93","article-title":"PRRT for malignant pheochromocytomas and paragangliomas: the Singapore General Hospital Experience. Abstract N9","volume":"103","author":"Loh","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref2221","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1210\/jc.2002-021069","article-title":"The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors","volume":"87","author":"Koch","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"ref211","volume-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2010"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","article-title":"Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma","volume":"4","author":"Tanabe","year":"2013","journal-title":"Horm Cancer"},{"key":"ref2641","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.12688\/f1000research.12419.1","article-title":"Predictors of outcome in phaeochromocytomas and paragangliomas","volume":"6","author":"Nicolas","year":"2017","journal-title":"F1000 Res"},{"key":"ref2901","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jamcollsurg.2008.08.013","article-title":"Proposed staging system for colon carcinoid tumors based on an analysis of 2,459 patients","volume":"207","author":"Landry","year":"2008","journal-title":"J Am Coll Surg"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.amjsurg.2014.11.012","article-title":"Effectiveness and safety of laparoscopic adrenalectomy of large pheochromocytoma: a prospective, nonrandomized, controlled study","volume":"210","author":"Wang","year":"2015","journal-title":"Am J Surg"},{"key":"ref1611","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"key":"ref2441","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.15.S1.1","article-title":"The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas","volume":"15","author":"Zeiger","year":"2009","journal-title":"Endocr Pract"},{"key":"ref2431","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing\u2019s syndrome: an Endocrine Society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jjco\/hyp173","article-title":"Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas","volume":"40","author":"Iwasa","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ijc.2910540310","article-title":"p53 mutations in sporadic adrenocortical tumors","volume":"54","author":"Ohgaki","year":"1993","journal-title":"Int J Cancer"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/CRD.0b013e3181a6de40","article-title":"Paragangliomas: etiology, presentation, and management","volume":"17","author":"Joynt","year":"2009","journal-title":"Cardiol Rev"},{"key":"ref2121","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12029-015-9689-0","article-title":"Treatment of high-grade metastatic pancreatic neuroendocrine carcinoma with FOLFIRINOX","volume":"46","author":"Zhu","year":"2015","journal-title":"J Gastrointest Cancer"},{"key":"ref2461","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/bjs.10414","article-title":"European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma","volume":"104","author":"Gaujoux","year":"2017","journal-title":"Br J Surg"},{"key":"ref2351","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2581","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"ref2881","first-page":"101","article-title":"Peptide receptor radionuclide therapy (PRRT) for progressive, somatostatin receptor positive pheochromocytoma\/paraganglioma. Abstract from the Society of Nuclear Medicine, Inc","volume":"49","author":"Prasad","year":"2008","journal-title":"J Nucl Med"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J Immunother Cancer"},{"key":"ref821","first-page":"1444","article-title":"Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors","volume":"78","author":"Gicquel","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2521","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1200\/JCO.2008.17.2775","article-title":"Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma","volume":"27","author":"Veytsman","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/cen.13434","article-title":"Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"87","author":"Hamidi","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref2421","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EJE-09-0627","article-title":"The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective","volume":"163","author":"Guignat","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"ref2451","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1210\/jc.2012-2198","article-title":"Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma","volume":"98","author":"Raymond","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/j.seminoncol.2016.08.007","article-title":"Genetic predisposition to endocrine tumors: diagnosis, surveillance and challenges in care","volume":"43","author":"Petr","year":"2016","journal-title":"Semin Oncol"},{"key":"ref2341","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref1561","volume-title":"WHO Classification of Tumors. Digestive System Tumours","author":"Klimstra","year":"2019"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12032-016-0737-9","article-title":"Peptide receptor radionuclide therapy for metastatic paragangliomas","volume":"33","author":"Pinato","year":"2016","journal-title":"Med Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00428-007-0450-3","article-title":"Hereditary neuroendocrine tumors of the gastroenteropancreatic system","volume":"451","author":"Anlauf","year":"2007","journal-title":"Virchows Arch"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/EJE-17-0990","article-title":"Management of endocrine disease: diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited","volume":"179","author":"Williams","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref2051","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/cncr.31124","article-title":"Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases","volume":"124","author":"Dasari","year":"2018","journal-title":"Cancer"},{"key":"ref2171","doi-asserted-by":"crossref","first-page":"S711","DOI":"10.1016\/j.annonc.2020.08.1370","article-title":"A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)","volume":"31","author":"Capdevila","year":"2020","journal-title":"Ann Oncol"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PAS.0b013e3182417d36","article-title":"Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors","volume":"36","author":"Yachida","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"ref1491","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000226789","article-title":"SBLA syndrome revisited","volume":"47","author":"Lynch","year":"1990","journal-title":"Oncology"},{"key":"ref2511","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bjc.1994.183","article-title":"Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients","volume":"69","author":"Haak","year":"1994","journal-title":"Br J Cancer"},{"key":"ref2851","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jso.24553","article-title":"Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas","volume":"115","author":"Nastos","year":"2017","journal-title":"J Surg Oncol"},{"key":"ref2611","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma\/paraganglioma: a National Institutes of Health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr Pract"},{"key":"ref2961","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1507\/endocrj.EJ14-0211","article-title":"Effects and safety of (1)(3)(1)I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry","volume":"61","author":"Yoshinaga","year":"2014","journal-title":"Endocr J"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11605-014-2624-z","article-title":"Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection","volume":"19","author":"Curran","year":"2015","journal-title":"J Gastrointest Surg"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"ref221","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"ref1961","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1245\/s10434-019-08049-5","article-title":"Surgery with radical intent: is there an indication for G3 neuroendocrine neoplasms?","volume":"27","author":"Merola","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/CRD.0b013e3181a6de40","article-title":"Paragangliomas: etiology, presentation, and management","volume":"17","author":"Joynt","year":"2009","journal-title":"Cardiol Rev"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00428-006-0250-1","article-title":"TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system","volume":"449","author":"Rindi","year":"2006","journal-title":"Virchows Arch"},{"key":"ref2671","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4149\/endo_2011_02_65","article-title":"Phaeochromocytoma: a catecholamine and oxidative stress disorder","volume":"45","author":"Pacak","year":"2011","journal-title":"Endocr Regul"},{"key":"ref2001","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"ref1391","first-page":"101","article-title":"Peptide receptor radionuclide therapy (PRRT) for progressive, somatostatin receptor positive pheochromocytoma\/paraganglioma. Abstract from the Society of Nuclear Medicine, Inc","volume":"49","author":"Prasad","year":"2008","journal-title":"J Nucl Med"},{"key":"ref2371","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"ref2591","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","article-title":"The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer","volume":"39","author":"Chen","year":"2010","journal-title":"Pancreas"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2010.33.0688","article-title":"Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression","volume":"29","author":"Panzuto","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma\/paraganglioma: a National Institutes of Health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr Pract"},{"key":"ref2751","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijsu.2012.12.007","article-title":"Laparoscopic adrenalectomy, a safe procedure for pheochromocytoma. A retrospective review of clinical series","volume":"11","author":"Conzo","year":"2013","journal-title":"Int J Surg"},{"key":"ref1841","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.2011.35.1817","article-title":"Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors","volume":"29","author":"Strosberg","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","journal-title":"Virchows Arch"},{"key":"ref2561","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"ref2911","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"109","author":"Averbuch","year":"1988","journal-title":"Ann Intern Med"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cncr.23549","article-title":"Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors","volume":"113","author":"Pape","year":"2008","journal-title":"Cancer"},{"key":"ref2471","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1245\/s10434-015-4900-x","article-title":"Open versus laparoscopic adrenalectomy for adrenocortical carcinoma: a meta-analysis of surgical and oncological outcomes","volume":"23","author":"Autorino","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1245\/s10434-013-2942-5","article-title":"Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing","volume":"20","author":"Fishbein","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"ref2821","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"key":"ref1531","first-page":"1813","volume-title":"Cancer: Principles and Practice of Oncology","author":"DeVita","year":"2001"},{"key":"ref1731","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1001\/archsurg.143.7.664","article-title":"Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system","volume":"143","author":"Landry","year":"2008","journal-title":"Arch Surg"},{"key":"ref2101","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1530\/ERC-12-0002","article-title":"FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3","volume":"19","author":"Hentic","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000369275","article-title":"Grading of neuroendocrine neoplasms: mitoses and Ki-67 are both essential","volume":"100","author":"van Velthuysen","year":"2014","journal-title":"Neuroendocrinology"},{"key":"ref71","volume-title":"WHO Classification of Tumors. Digestive System Tumours","author":"Klimstra","year":"2019"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"key":"ref2551","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000347","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00428-007-0450-3","article-title":"Hereditary neuroendocrine tumors of the gastroenteropancreatic system","volume":"451","author":"Anlauf","year":"2007","journal-title":"Virchows Arch"},{"key":"ref1631","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2010.33.0688","article-title":"Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression","volume":"29","author":"Panzuto","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref2161","first-page":"cncr.33591","article-title":"A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: high-grade neuroendocrine neoplasm cohort","author":"Patel","year":"2021","journal-title":"Cancer"},{"key":"ref2031","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"key":"ref1861","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","article-title":"Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival","volume":"19","author":"Halfdanarson","year":"2008","journal-title":"Ann Oncol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-15-0548","article-title":"Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas","volume":"22","author":"Tang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jnci\/djv053","article-title":"Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene","volume":"107","author":"Casc\u00f3n","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"ref2391","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1148\/radiol.2223010766","article-title":"Adrenal masses: characterization with combined unenhanced and delayed enhanced CT","volume":"222","author":"Caoili","year":"2002","journal-title":"Radiology"},{"key":"ref2831","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2331","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref1691","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-60049-4","volume-title":"Histological typing of lung and pleural tumours","author":"Travis","year":"1999"},{"key":"ref2141","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/MPA.0000000000001529","article-title":"Efficacy of second-line chemotherapy in extrapulmonary neuroendocrine carcinoma","volume":"49","author":"McGarrah","year":"2020","journal-title":"Pancreas"},{"key":"ref2571","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1023\/A:1008377915129","article-title":"Streptozocin and o,p\u2019DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use","volume":"11","author":"Khan","year":"2000","journal-title":"Ann Oncol"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"ref2871","first-page":"254","article-title":"Treatment of paragangliomas with lutetium-177-octreotate based peptide receptor radionuclide therapy. Abstract N16","volume":"105","author":"Smit Duijzentkunst","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref1381","first-page":"254","article-title":"Treatment of paragangliomas with lutetium-177-octreotate based peptide receptor radionuclide therapy. Abstract N16","volume":"105","author":"Smit Duijzentkunst","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref2041","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-16-3135","article-title":"Rb Loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a Japanese multicenter pancreatic NEN-G3 study","volume":"23","author":"Hijioka","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref201","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-60049-4","volume-title":"Histological typing of lung and pleural tumours","author":"Travis","year":"1999"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"109","author":"Averbuch","year":"1988","journal-title":"Ann Intern Med"},{"key":"ref2541","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J Immunother Cancer"},{"key":"ref41","first-page":"1813","volume-title":"Cancer: Principles and Practice of Oncology","author":"DeVita","year":"2001"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref1821","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11605-014-2624-z","article-title":"Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection","volume":"19","author":"Curran","year":"2015","journal-title":"J Gastrointest Surg"},{"key":"ref1061","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000347","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.2011.35.1817","article-title":"Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors","volume":"29","author":"Strosberg","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1711","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"ref2731","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/jmedgenet-2012-101192","article-title":"Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis","volume":"49","author":"van Hulsteijn","year":"2012","journal-title":"J Med Genet"},{"key":"ref1551","first-page":"322","volume-title":"WHO Classification of Tumours of the Digestive System","author":"Bosman","year":"2010"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/erc.1.01017","article-title":"Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization","volume":"12","author":"Panzuto","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"ref2361","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"ref2891","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12032-016-0737-9","article-title":"Peptide receptor radionuclide therapy for metastatic paragangliomas","volume":"33","author":"Pinato","year":"2016","journal-title":"Med Oncol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.surg.2008.05.005","article-title":"A proposed staging system for rectal carcinoid tumors based on an analysis of 4701 patients","volume":"144","author":"Landry","year":"2008","journal-title":"Surgery"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"9032753","DOI":"10.1155\/2019\/9032753","article-title":"CAPTEM in metastatic well-differentiated intermediate to high grade neuroendocrine tumors: a single centre experience","volume":"2019","author":"Sahu","year":"2019","journal-title":"J Oncol"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-16-3135","article-title":"Rb Loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a Japanese multicenter pancreatic NEN-G3 study","volume":"23","author":"Hijioka","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref2861","first-page":"93","article-title":"PRRT for malignant pheochromocytomas and paragangliomas: the Singapore General Hospital Experience. Abstract N9","volume":"103","author":"Loh","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1200\/JCO.2011.34.6353","article-title":"Metastatic pheochromocytoma\/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations","volume":"29","author":"King","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1251","volume-title":"GeneReviews","author":"Else","year":"2008"},{"key":"ref1781","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/cam4.1336","article-title":"Assessment of the American Joint Commission on Cancer 8th edition staging system for patients with pancreatic neuroendocrine tumors: A Surveillance, Epidemiology, and End Results analysis","volume":"7","author":"Li","year":"2018","journal-title":"Cancer Med"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N Engl J Med"},{"key":"ref1741","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.surg.2008.05.005","article-title":"A proposed staging system for rectal carcinoid tumors based on an analysis of 4701 patients","volume":"144","author":"Landry","year":"2008","journal-title":"Surgery"},{"key":"ref1881","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/PAS.0b013e3181ce1447","article-title":"Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set","volume":"34","author":"Klimstra","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2","article-title":"Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p\u2019DDD) levels on the treatment of patients with adrenocortical carcinoma","volume":"92","author":"Baudin","year":"2001","journal-title":"Cancer"},{"key":"ref1481","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/PAS.0000000000000662","article-title":"A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas","volume":"40","author":"Tang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"key":"ref2711","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","article-title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma","volume":"18","author":"Burnichon","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1530\/ERC-13-0027","article-title":"Are G3 ENETS neuroendocrine neoplasms heterogeneous?","volume":"20","author":"V\u00e9layoudom-C\u00e9phise","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"ref1981","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/MPA.0000000000001529","article-title":"Efficacy of second-line chemotherapy in extrapulmonary neuroendocrine carcinoma","volume":"49","author":"McGarrah","year":"2020","journal-title":"Pancreas"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/cncr.32750","article-title":"Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: a randomized phase 2 study","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"key":"ref1681","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000369275","article-title":"Grading of neuroendocrine neoplasms: mitoses and Ki-67 are both essential","volume":"100","author":"van Velthuysen","year":"2014","journal-title":"Neuroendocrinology"},{"key":"ref2081","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000497336","article-title":"Carboplatin in combination with oral or intravenous etoposide for extra-pulmonary, poorly-differentiated neuroendocrine carcinomas","volume":"109","author":"Frizziero","year":"2019","journal-title":"Neuroendocrinology"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.12688\/f1000research.12419.1","article-title":"Predictors of outcome in phaeochromocytomas and paragangliomas","volume":"6","author":"Nicolas","year":"2017","journal-title":"F1000 Res"},{"key":"ref2291","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ijc.2910540310","article-title":"p53 mutations in sporadic adrenocortical tumors","volume":"54","author":"Ohgaki","year":"1993","journal-title":"Int J Cancer"},{"key":"ref2231","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000226789","article-title":"SBLA syndrome revisited","volume":"47","author":"Lynch","year":"1990","journal-title":"Oncology"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijsu.2012.12.007","article-title":"Laparoscopic adrenalectomy, a safe procedure for pheochromocytoma. A retrospective review of clinical series","volume":"11","author":"Conzo","year":"2013","journal-title":"Int J Surg"},{"key":"ref2311","first-page":"1444","article-title":"Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors","volume":"78","author":"Gicquel","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2012.48.0988","article-title":"Adrenocortical carcinoma is a lynch syndrome-associated cancer","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref1471","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1507\/endocrj.EJ14-0211","article-title":"Effects and safety of (1)(3)(1)I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry","volume":"61","author":"Yoshinaga","year":"2014","journal-title":"Endocr J"},{"key":"ref1591","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","journal-title":"Virchows Arch"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1158\/1078-0432.CCR-20-0621","article-title":"Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers","volume":"26","author":"Klein","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref2261","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref1851","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jamcollsurg.2007.05.009","article-title":"Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors","volume":"205","author":"Bilimoria","year":"2007","journal-title":"J Am Coll Surg"},{"key":"ref2061","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jjco\/hyp173","article-title":"Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas","volume":"40","author":"Iwasa","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"ref2401","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/EJE-17-0990","article-title":"Management of endocrine disease: diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited","volume":"179","author":"Williams","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/PAS.0000000000000408","article-title":"The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms","volume":"39","author":"Basturk","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.2013.51.1477","article-title":"Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors","volume":"31","author":"Kim","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/PAS.0b013e3181ce1447","article-title":"Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set","volume":"34","author":"Klimstra","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1210\/clinem\/dgaa606","article-title":"Evolution of the primary aldosteronism syndrome: updating the approach","volume":"105","author":"Vaidya","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/cncr.31124","article-title":"Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases","volume":"124","author":"Dasari","year":"2018","journal-title":"Cancer"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2018.36.15_suppl.4005","article-title":"Azedra (iobenguane I 131) in patients with malignant, recurrent and\/or unresectable pheochromocytoma or paraganglioma (PPGL): updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study","volume":"36","author":"Pryma","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.amjsurg.2008.07.042","article-title":"A proposed staging system for small bowel carcinoid tumors based on an analysis of 6,380 patients","volume":"196","author":"Landry","year":"2008","journal-title":"Am J Surg"},{"key":"ref1991","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","volume":"8","author":"Merino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref831","first-page":"2559","article-title":"Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors","volume":"82","author":"Gicquel","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","article-title":"Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival","volume":"19","author":"Halfdanarson","year":"2008","journal-title":"Ann Oncol"},{"key":"ref2501","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2","article-title":"Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p\u2019DDD) levels on the treatment of patients with adrenocortical carcinoma","volume":"92","author":"Baudin","year":"2001","journal-title":"Cancer"},{"key":"ref61","first-page":"322","volume-title":"WHO Classification of Tumours of the Digestive System","author":"Bosman","year":"2010"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00428-006-0250-1","article-title":"TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system","volume":"449","author":"Rindi","year":"2006","journal-title":"Virchows Arch"},{"key":"ref2301","first-page":"790","article-title":"p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies","volume":"78","author":"Reincke","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2781","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jcem-72-2-455","article-title":"Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma","volume":"72","author":"Krempf","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"ref1971","doi-asserted-by":"crossref","first-page":"9032753","DOI":"10.1155\/2019\/9032753","article-title":"CAPTEM in metastatic well-differentiated intermediate to high grade neuroendocrine tumors: a single centre experience","volume":"2019","author":"Sahu","year":"2019","journal-title":"J Oncol"},{"key":"ref1891","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1634\/theoncologist.2015-0476","article-title":"Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement","volume":"21","author":"Coriat","year":"2016","journal-title":"Oncologist"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"key":"ref2691","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.2012.47.1912","article-title":"New syndrome of paraganglioma and somatostatinoma associated with polycythemia","volume":"31","author":"Pacak","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.acra.2017.12.005","article-title":"Combining washout and noncontrast data from adrenal protocol CT: improving diagnostic performance","volume":"25","author":"Ng","year":"2018","journal-title":"Acad Radiol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000497336","article-title":"Carboplatin in combination with oral or intravenous etoposide for extra-pulmonary, poorly-differentiated neuroendocrine carcinomas","volume":"109","author":"Frizziero","year":"2019","journal-title":"Neuroendocrinology"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc2031965","article-title":"The spectrum of benefit from checkpoint blockade in hypermutated tumors","volume":"384","author":"Rousseau","year":"2021","journal-title":"N Engl J Med"},{"key":"ref1641","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/erc.1.01017","article-title":"Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization","volume":"12","author":"Panzuto","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","article-title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma","volume":"18","author":"Burnichon","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref2681","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1245\/s10434-013-2942-5","article-title":"Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing","volume":"20","author":"Fishbein","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"S711","DOI":"10.1016\/j.annonc.2020.08.1370","article-title":"A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)","volume":"31","author":"Capdevila","year":"2020","journal-title":"Ann Oncol"},{"key":"ref811","first-page":"790","article-title":"p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies","volume":"78","author":"Reincke","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2931","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1245\/s10434-015-4900-x","article-title":"Open versus laparoscopic adrenalectomy for adrenocortical carcinoma: a meta-analysis of surgical and oncological outcomes","volume":"23","author":"Autorino","year":"2016","journal-title":"Ann Surg Oncol"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/19\/7\/article-p839.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/19\/7\/article-p839.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T14:33:20Z","timestamp":1636727600000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/19\/7\/article-p839.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":296,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2021.0032","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}